Financial News

Novo Nordisk FY24 Results

Diabetes and Obesity care increased by 26%, driven by GLP-1 diabetes sales growth of 21% and Obesity care growing by 56%.

By: Kristin Brooks

Managing Editor, Contract Pharma

Image: Novo Nordisk

Novo Nordisk

FY Revenues: $40.6 billion (+25%)

FY Earnings: $14.1 billion (+21%)

Comments: Sales in North America Operations increased by 30% in Danish kroner. Sales in International Operations increased by 17% in Danish kroner.

Sales within Diabetes and Obesity care increased by 26% in Danish kroner to DKK 271.8 billion, mainly driven by GLP-1 diabetes sales growth of 21% in Danish kroner and Obesity care growing by 56% in Danish kroner to DKK 65.1 billion. Rare disease sales increased by 9% in Danish kroner.

In December 2024, Novo Nordisk announced that the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings was completed.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters